 |
|
Kidney Cancer Trial Results
1. Sorafenib Delays Progression of Metastatic Kidney Cancer
(Posted: 02/07/2007, Updated: 06/08/2009) - The targeted drug sorafenib (Nevaxar®), which delays disease progression in patients with metastatic kidney cancer, may also improve survival of such patients, according to the May 18, 2009, Journal of Clinical Oncology.
2. Everolimus Extends Progression-Free Survival in Advanced Kidney Cancer
(Posted: 07/30/2008) - A phase III trial testing the drug everolimus in patients with advanced kidney cancer was stopped after an interim analysis showed a significant improvement in progression-free survival, the drug's manufacturer, Novartis, reported February 28, 2008.
3. Sorafenib Increases the Risk of High Blood Pressure
(Posted: 04/02/2008) - Combined data from nine studies showed that patients receiving the standard amount of sorafenib (Nexavar®), an anticancer drug that interferes with a tumor's blood supply, run a significant risk of high blood pressure (hypertension), according to the February 2008 Lancet Oncology.
4. Bevacizumab (Avastin®) Benefits Some Patients With Advanced Kidney Cancer
(Posted: 06/20/2007, Reviewed: 01/22/2008) - Addition of the targeted drug bevacizumab (Avastin®) to interferon alpha staved off disease progression for significantly longer than a placebo in patients with advanced kidney cancer, according to findings presented at the 2007 ASCO meeting in Chicago.
5. Whole Brain Radiation May be Postponed in Cancer Patients with Limited Metastasis to the Brain
(Posted: 08/28/2006) - Whole brain radiation therapy can be delayed without compromising survival in patients with four or fewer contained metastases to the brain, according to the June 7, 2006, issue of the Journal of the American Medical Association.
1 2 Next >
|
|
|
